Global Cardiovascular Disease Market Size Study, by Diseases, by Treatment, by Route of Administration, by End-User, by Distribution Channel, and Regional Forecasts 2022-2032

Description

Global Cardiovascular Disease Market is valued at approximately USD 171.55 Million in 2023 and is expected to expand at a robust growth rate of 5% during the forecast period from 2024 to 2032. Cardiovascular diseases, which affect the heart and blood vessels, have emerged as one of the leading causes of global mortality. This category of diseases predominantly affects the elderly population, necessitating the consistent use of cardiovascular medications. The severity of cardiovascular conditions often demands prolonged use of drugs, as abrupt discontinuation can pose significant risks to a patient's health.

The market is driven by several key factors, including the alarming increase in the incidence of cardiovascular diseases due to sedentary lifestyles and aging populations. According to the WHO, the adoption of inactive lifestyles is prevalent among 60%-85% of the population, contributing to the rising demand for cardiovascular drugs. Furthermore, regulatory approvals from the FDA, such as the approvals for Selexipag tablets and Norliqva oral solutions, highlight the growing pipeline of cardiovascular treatments. These developments are critical in addressing various cardiovascular conditions, thereby propelling market growth.

In addition to this, opportunities abound in the rising prevalence of hypertension, especially among the aging population. As the elderly population expands globally, so too does the demand for hypertension treatments, further fueling market growth. Retail pharmacies are also playing an increasingly prominent role in drug distribution, with their accessibility and convenience attracting cardiovascular patients.

However, challenges remain, particularly the lack of skilled healthcare professionals capable of administering complex cardiovascular treatments. Additionally, side effects associated with cardiovascular drugs, such as nausea, upset stomach, and erectile dysfunction, could hinder market expansion. Nevertheless, the growing focus on innovative treatment approaches and increasing investment in research and development continues to drive the industry forward.

The key regions considered for the Global Cardiovascular Disease Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is a dominating region in the Global Cardiovascular Disease Market in terms of revenue. The market growth in the region is being attributed to factors including leading research and development initiatives, advanced healthcare infrastructure, and a high prevalence of heart diseases. Whereas, the market in Asia Pacific is anticipated to grow at the fastest rate over the forecast period fueled by its burgeoning healthcare facilities, numerous generic drug manufacturers, and supportive government initiatives.

Major market players included in this report are:

F. Hoffmann-La Roche Ltd
Bayer AG
Novartis AG
Pfizer Inc.
GSK Plc
Sun Pharmaceutical Industries Ltd
Mylan N.V.
Teva Pharmaceutical Industries Ltd
Zydus Group
Glenmark Pharmaceuticals Inc.
Fresenius Kabi AG
Lupin
Capricor Therapeutics
Zensun
Janssen Pharmaceuticals, Inc.

The detailed segments and sub-segments of the market are explained below:

By Diseases:

Hypertension
Dyslipidemia
Inflammatory Heart Disease
Ischemic Heart Disease
Others

By Treatment:

Antiplatelet Agents
Beta-Blockers
Angiotensin-Converting Enzyme Inhibitors
Others

By Route of Administration:

Oral
Parenteral
Others

By End-User:

Hospitals
Homecare
Specialty Clinics
Others

By Distribution Channel:

Hospital Pharmacy
Online Pharmacy
Retail Pharmacy

By Region:

North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Middle East & Africa
Saudi Arabia
South Africa
RoMEA

Years considered for the study are as follows:

Historical year - 2022
Base year - 2023
Forecast period - 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and regional level analysis for each market segment.
Detailed analysis of geographical landscape with Country-level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approaches.
Analysis of competitive structure of the market.
Demand-side and supply-side analysis of the market.

Chapter 1. Global Cardiovascular Disease Market Executive Summary

1.1. Global Cardiovascular Disease Market Size & Forecast (2022-2032)
1.2. Regional Summary
1.3. Segmental Summary
- 1.3.1. By Diseases
- 1.3.2. By Treatment
- 1.3.3. By Route of Administration
- 1.3.4. By End-User
- 1.3.5. By Distribution Channel
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Cardiovascular Disease Market Definition and Research Assumptions

2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
- 2.3.1. Inclusion & Exclusion
- 2.3.2. Limitations
- 2.3.3. Supply Side Analysis
- 2.3.4. Demand Side Analysis
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates

Chapter 3. Global Cardiovascular Disease Market Dynamics

3.1. Market Drivers
- 3.1.1. Increase in Cardiovascular Diseases
- 3.1.2. Rising FDA Approvals
3.2. Market Challenges
- 3.2.1. Lack of Skilled Professionals
- 3.2.2. Side Effects of Cardioselective Beta Blockers
3.3. Market Opportunities
- 3.3.1. Rising Prevalence of Hypertension
- 3.3.2. Increasing Demand for Retail Pharmacies

Chapter 4. Global Cardiovascular Disease Market Industry Analysis

4.1. Porter's Five Forces Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
4.2. PESTEL Analysis
- 4.2.1. Political
- 4.2.2. Economical
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal
4.3. Top Investment Opportunity
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Analyst Recommendation & Conclusion

Chapter 5. Global Cardiovascular Disease Market Size & Forecasts by Diseases (2022-2032)

5.1. Segment Dashboard
5.2. Global Cardiovascular Disease Market: Disease Revenue Trend Analysis, 2022 & 2032 (USD Million)
- 5.2.1. Hypertension
- 5.2.2. Dyslipidemia
- 5.2.3. Inflammatory Heart Disease
- 5.2.4. Ischemic Heart Disease
- 5.2.5. Others

Chapter 6. Global Cardiovascular Disease Market Size & Forecasts by Treatment (2022-2032)

6.1. Segment Dashboard
6.2. Global Cardiovascular Disease Market: Treatment Revenue Trend Analysis, 2022 & 2032 (USD Million)
- 6.2.1. Antiplatelet Agents
- 6.2.2. Beta-Blockers
- 6.2.3. Angiotensin-Converting Enzyme Inhibitors
- 6.2.4. Others

Chapter 7. Global Cardiovascular Disease Market Size & Forecasts by Route of Administration (2022-2032)

7.1. Segment Dashboard
7.2. Global Cardiovascular Disease Market: Route of Administration Revenue Trend Analysis, 2022 & 2032 (USD Million)
- 7.2.1. Oral
- 7.2.2. Parenteral
- 7.2.3. Others

Chapter 8. Global Cardiovascular Disease Market Size & Forecasts by End-User (2022-2032)

8.1. Segment Dashboard
8.2. Global Cardiovascular Disease Market: End-User Revenue Trend Analysis, 2022 & 2032 (USD Million)
- 8.2.1. Hospitals
- 8.2.2. Homecare
- 8.2.3. Specialty Clinics
- 8.2.4. Others

Chapter 9. Global Cardiovascular Disease Market Size & Forecasts by Distribution Channel (2022-2032)

9.1. Segment Dashboard
9.2. Global Cardiovascular Disease Market: Distribution Channel Revenue Trend Analysis, 2022 & 2032 (USD Million)
- 9.2.1. Hospital Pharmacy
- 9.2.2. Online Pharmacy
- 9.2.3. Retail Pharmacy

Chapter 10. Global Cardiovascular Disease Market Size & Forecasts by Region (2022-2032)

10.1. North America Cardiovascular Disease Market
- 10.1.1. U.S. Cardiovascular Disease Market
  - 10.1.1.1. Diseases breakdown size & forecasts, 2022-2032
  - 10.1.1.2. Treatment breakdown size & forecasts, 2022-2032
  - 10.1.1.3. Route of Administration breakdown size & forecasts, 2022-2032
  - 10.1.1.4. End User breakdown size & forecasts, 2022-2032
  - 10.1.1.5. Distribution Channel breakdown size & forecasts, 2022-2032
- 10.1.2. Canada Cardiovascular Disease Market
- 10.1.3. Mexico Cardiovascular Disease Market
10.2. Europe Cardiovascular Disease Market
- 10.2.1. U.K. Cardiovascular Disease Market
- 10.2.2. Germany Cardiovascular Disease Market
- 10.2.3. France Cardiovascular Disease Market
- 10.2.4. Italy Cardiovascular Disease Market
- 10.2.5. Spain Cardiovascular Disease Market
- 10.2.6. Rest of Europe Cardiovascular Disease Market
10.3. Asia Pacific Cardiovascular Disease Market
- 10.3.1. China Cardiovascular Disease Market
- 10.3.2. Japan Cardiovascular Disease Market
- 10.3.3. India Cardiovascular Disease Market
- 10.3.4. Australia Cardiovascular Disease Market
- 10.3.5. South Korea Cardiovascular Disease Market
- 10.3.6. Rest of Asia Pacific Cardiovascular Disease Market
10.4. Latin America Cardiovascular Disease Market
- 10.4.1. Brazil Cardiovascular Disease Market
- 10.4.2. Argentina Cardiovascular Disease Market
- 10.4.3. Rest of Latin America Cardiovascular Disease Market
10.5. Middle East & Africa Cardiovascular Disease Market
- 10.5.1. Saudi Arabia Cardiovascular Disease Market
- 10.5.2. South Africa Cardiovascular Disease Market
- 10.5.3. Rest of Middle East & Africa Cardiovascular Disease Market

Chapter 11. Competitive Intelligence

11.1. Key Company SWOT Analysis
11.2. Top Market Strategies
11.3. Company Profiles
- 11.3.1. F. Hoffmann-La Roche Ltd
  - 11.3.1.1. Key Information
  - 11.3.1.2. Overview
  - 11.3.1.3. Financial (Subject to Data Availability)
  - 11.3.1.4. Product Summary
  - 11.3.1.5. Market Strategies
- 11.3.2. Bayer AG
- 11.3.3. Novartis AG
- 11.3.4. Pfizer Inc.
- 11.3.5. GSK Plc
- 11.3.6. Sun Pharmaceutical Industries Ltd
- 11.3.7. Mylan N.V.
- 11.3.8. Teva Pharmaceutical Industries Ltd
- 11.3.9. Zydus Group
- 11.3.10. Glenmark Pharmaceuticals Inc.
- 11.3.11. Fresenius Kabi AG
- 11.3.12. Lupin
- 11.3.13. Capricor Therapeutics
- 11.3.14. Zensun
- 11.3.15. Janssen Pharmaceuticals, Inc.

Chapter 12. Research Process

12.1. Research Process
- 12.1.1. Data Mining
- 12.1.2. Analysis
- 12.1.3. Market Estimation
- 12.1.4. Validation
- 12.1.5. Publishing
12.2. Research Attributes